The INSPIRIS RESILIA valve: the world's most implanted surgical tissue valve
Learn why the INSPIRIS RESILIA valve is trusted by surgeons worldwide
Edwards Lifesciences at the 38th EACTS Annual Meeting
9 – 12 October 2024
|
Lisbon, Portugal
|
Get the most out of new insights and innovations with
Edwards Lifesciences
Join us for an engaging experience with hands-on training, expert-led sessions, and a showcase of our latest innovations.
Lunch Symposia
Thursday, 10 Oct 2024
12:15 - 13:30
|
Auditorium 7
|
Aortic regurgitation: treating patients across the spectrum
A comprehensive exploration of surgical strategies and techniques tailored to meet the diverse needs of patients, highlighting the crucial importance of timely diagnosis and intervention.
Chairs:
Filip Casselman, Belgium
Friday, 11 Oct 2024
12:15 - 13:30
|
Auditorium 7
|
New frontiers in mitral valve replacement
The latest advancements in mitral valve treatment, including minimally invasive approaches, innovations in valve technology, and the implementation of cardiac ERAS protocols.
Chairs:
Marjan Jahangiri, United Kingdom
Vinod Thourani, United States
Training Village: Pioneering Excellence in Cardiac Surgery
Elevate your skills at the Edwards Training Village, an interactive space where surgeons engage in state-of-the-art training simulations. Utilizing our latest RESILIA and transcatheter technologies, participants explore the latest in clinical practice and minimally invasive approaches under the direction of leading experts.
Daily
|
30 min
|
Edwards Training village, Room 1
|
Deep dive on RESILIA tissue technology
In this session, experts showcase advancements in tissue technology, review the latest clinical data on the durability of INSPIRIS aortic and MITRIS mitral valves, and outline the key steps for a MITRIS mitral valve implantation.
Daily
|
60 min
|
Edwards Training village, Room 2
|
State-of-the-art practice in cardiac surgery
Join our clinical education community and gain insights from experts on the latest practices in aortic and mitral valve surgery through engaging hands-on sessions.
Daily
|
60 min
|
Edwards Training village, Room 3
|
EVOQUE Valve Journey from Patient selection to Procedure
Immerse yourself in the latest transcatheter tricuspid valve replacement technology.
Daily
|
60 min
|
Edwards Training village, Room 3
|
Lifetime management in light of SAPIEN 3 Ultra RESILIA valve
Explore the newest advancements in transcatheter aortic valve technology and techniques, along with lifetime management strategies.
See how we are taking performance and durability to new heights
Stop by our booth for an exclusive experience with live sessions by leading cardiac surgeons, exploring the latest innovative technologies in the field.
Discover Edwards Lifesciences’ latest innovations
Join us at our booth to connect with your peers and discover our products through immersive and engaging experiences, featuring the latest data and studies on aortic and mitral valve surgery.
MITRIS RESILIA valve: Built to handle the pressure of the mitral position
Discover why MITRIS RESILIA is the latest Edwards innovation in mitral surgery
RESILIA tissue: Innovation that transformed the tissue valve landscape
The RESILIA tissue surgical valve portfolio is backed by a robust, growing base of clinical evidence attesting to its hemodynamic performance and durability
Recommended sessions
Wednesday 9 Oct 2024
15:45 – 18:00
|
2 hours 15 minutes
|
Auditorium 1
|
Part III: Mitral and Beyond (Techno-College)
Mini mitral valve replacement (Live) -
F. Bakhtiary,
Germany
Extracted from the 2024 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website.
Thursday 10 Oct 2024
15:15 – 16:15
|
1 hour
|
Auditorium 3+4 (Interactive)
|
The aortic valve exposed: from basic to experienced (Rapid Response)
Gender-based outcomes following aortic valve replacement:
A multicentre propensity score matching analysis - R. De Paulis, Italy
A multicentre propensity score matching analysis - R. De Paulis, Italy
Extracted from the 2024 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website.
Friday 11 Oct 2024
08:30 – 09:30
|
1 hour
|
Room 5A, Pav 5
|
Video-session on minimally invasive aortic valve replacement (Focus Session)
Quality of Life during Five-Years of follow-up after Minimally Invasive and Conventional Surgical
Aortic Valve Replacement: Results from a Randomized Controlled Trial - I. Klop , Netherlands
Aortic Valve Replacement: Results from a Randomized Controlled Trial - I. Klop , Netherlands
10:00 - 11:00
|
1 hour
|
Auditorium 1
|
Late Breaking Science: Aortic Valve Disease (Abstract)
7-Year follow-up of >1100 patients who received a contemporary pericardial aortic bioprostheses -
J. Sabik,
USA
Five-year real-world European results with a novel aortic bioproshesis in patients
with or without chronic kidney dysfunction - F. Onorati, Italy
with or without chronic kidney dysfunction - F. Onorati, Italy
Longitudinal Outcomes Following International Multicentre Experience
with Robotic Aortic Valve Replacement - V. Badhwar, Morgantown, USA
with Robotic Aortic Valve Replacement - V. Badhwar, Morgantown, USA
12:15 - 13:30
|
1 hour 15 minutes
|
Theatre 2
|
e-Poster Discussion 6
Six-year results of 4th generation pericardial valves in aortic position in young patients:
Real-world data from a multicenter European registry - F. Onorati and al., Italy
Real-world data from a multicenter European registry - F. Onorati and al., Italy
15:15 – 16:15
|
1 hour
|
Room 5B, Pav 5
|
The aortic valve unraveled
Outcomes of SAVR according to European and American guidelines:
Do we really need different recommendations? - A. D’Onofrio, Italy
Do we really need different recommendations? - A. D’Onofrio, Italy
Extracted from the 2024 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website.
Saturday 12 Oct 2024
8:30 – 09:30
|
1 hour
|
Room 3B, Pav 3
|
Life beyond P2
Improving the reproducibility of papillary muscle maneuvers in type IIIb MR:
Focus on papillary muscle geometry - E. Girdauskas , Germany
Focus on papillary muscle geometry - E. Girdauskas , Germany
Extracted from the 2024 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website.
Get Edwards updates
Sign up to our newsletter to stay up-to-date with the latest news and updates.
No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
Refer to device instructions for use for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in ViV procedures. VFit technology is available on sizes 19–25 mm.
Expert opinions, advice and all other information represent contributor’s views and not necessarily those of Edwards Lifesciences.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult https://eifu.edwards.com where applicable).